Get Free Demat Account*
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
By Dalal Street Investment Journal (DSIJ)
Dr Lal PathLabs reported a strong Q1 FY27, with revenue rising 19% YoY to ₹798 crore and net profit up 27% to ₹170 crore. EBITDA margins expanded to 31% and the company declared a 50% interim dividend. Share price surged 6% on the announcement.
Dr Lal PathLabs share price was trading at ₹1,867.5 on July 24, 2026, up 6% for the day. Trading volume stood at 10 lakh shares compared with the 30-day average volume of 6.5 lakh shares. The surge in activity came on the same day the company reported its consolidated results for the first quarter ended June 30, 2026, which showed broad-based improvement in revenue, margins and profitability.
Consolidated revenue for Q1 FY27 rose 19% YoY to ₹798 crore, from ₹670 crore in the same period last year. The growth was accompanied by meaningful cost discipline. Material consumption moved to ₹152 crore from ₹129 crore and fees to collection centres rose to ₹116 crore from ₹96 crore, broadly in line with volume expansion rather than indicating margin pressure.
EBITDA came in at ₹247 crore, up 29% YoY, with margins widening to 31.0% from 28.7% a year earlier. Profit before tax rose 26.3% to ₹229 crore, while net profit stood at ₹170 crore, up 27% YoY, with a net margin of 21.5% against 20.0% previously.
The company's board declared an interim dividend of 50%, equivalent to ₹5 per share.
Two inorganic moves announced alongside the results add a different dimension to the quarter's story. Dr Lal PathLabs has agreed to acquire an 80% equity stake in Sunshine Healthcare Limited, Ghana, a diagnostic business, for a consideration not exceeding GHS 45.6 million. The move marks an extension into the African diagnostics market, a geography where demand for organised healthcare services is growing but formal diagnostic infrastructure remains relatively underdeveloped.
In addition, the company has also agreed to acquire a 30% equity stake in Neuome Technologies Private Limited, which operates in sample preservation and biobanking solutions, for a consideration not exceeding ₹3.5 crore. Biobanking sits at the intersection of diagnostics and life sciences research. The investment gives Dr Lal PathLabs a foothold in an adjacent, early-stage segment.
Dr Lal PathLabs is one of India's largest diagnostic chains, offering a broad range of pathology, radiology and related healthcare tests. As of March 31, 2026, the company operated 312 clinical laboratories, including national reference labs in Delhi, Kolkata, Bangalore and Mumbai as well as 7,727 patient service centres and 13,935 pick-up points. Its customer base spans individual patients, hospitals, corporate clients and other healthcare providers.
Source: Dalal Street Investment Journal (DSIJ),BSE, NSE
SEBI Registered Research Analyst (INH000006396).
Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise.
Disclaimer :
Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading